ArticleFrontiers in genetics2026
Polygenic risk score and phenome-wide association study of the Epstein-Barr virus antibody response.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Epstein-Barr virus (EBV) infection is nearly ubiquitous and has established links to malignancy and autoimmune disease. Here we evaluate the genetic factors influencing the humoral immune response to EBV and establish a polygenic risk score (PRS) for anti-EBNA1 responses. Methods: We conducted a multi-biobank genetic study for the serologic humoral IgG antibody response to EBV-EBNA1, including data from the UK Biobank (UKB, N = 9695 individuals) and the Milieu Intérieur (MI) cohort from Institute Pasteur (IP) (N = 1000), as well as GWAS summary statistics for individuals of African ancestry (N = 4365). We divided the cohort into discovery and validation, performed GWAS analyses, and developed a PRS using a Bayesian multi-ancestry approach application (PRS-CSx). After successfully validating PRS predictive performance, we then applied PheWAS analyses to all UKB datasets. Results: Consistent with a previous report, our GWAS analyses identified an association at chromosome 6 within the MHC region as the most significant SNP (rs6927022; p = 8.21 × 10 Discussion: We developed and validated a multi-ancestry PRS for EBNA1 IgG response that enables genetic profiling of EBV antibody responsiveness in genotyped cohorts lacking serologic measurements. PheWAS results support shared and divergent genetic relationships between EBV antibody response and autoimmune disease, motivating mechanistic and longitudinal follow-up studies. Further research is needed to evaluate the future implementation of this PRS in the clinic to improve long-term health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.